.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Fuji
Julphar
US Army
Colorcon
Cipla
Farmers Insurance
Cerilliant
Queensland Health
Accenture

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,053,092 protect, and when does it expire?


Patent ► Subscribe protects ABILIFY and is included in three NDAs. There have been three Paragraph IV challenges on Abilify.

Summary for Patent: ► Subscribe

Title:5-HT1a receptor subtype agonist
Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s): Jordon; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:10/055,915
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Otsuka
ABILIFY
aripiprazole
SOLUTION;ORAL021713-001Dec 10, 2004DISCNYesNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET, ORALLY DISINTEGRATING;ORAL021729-002Jun 7, 2006DISCNNoNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET, ORALLY DISINTEGRATING;ORAL021729-003Jun 7, 2006DISCNNoNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET, ORALLY DISINTEGRATING;ORAL021729-004Jun 7, 2006DISCNYesNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET, ORALLY DISINTEGRATING;ORAL021729-005Jun 7, 2006DISCNYesNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET;ORAL021436-006Nov 15, 2002ABRXYesNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET;ORAL021436-005Nov 15, 2002ABRXYesYes► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET;ORAL021436-001Nov 15, 2002ABRXYesYes► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET;ORAL021436-002Nov 15, 2002ABRXYesNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka
ABILIFY
aripiprazole
TABLET;ORAL021436-003Nov 15, 2002ABRXYesNo► Subscribe► Subscribe TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,030,3125-HT1A receptor subtype agonist► Subscribe
8,642,600Method of treating autism► Subscribe
8,623,874Method of treating neurodegenerative diseases► Subscribe
8,604,041Method of treating panic disorder► Subscribe
9,387,2075-HT1A receptor subtype agonist► Subscribe
9,006,2485-HT.sub.1A receptor subtype agonist► Subscribe
9,089,567Method of treating cognitive impairments and schizophrenias► Subscribe
8,426,423Method of treating Attention Deficit Hyper-Activity Disorder► Subscribe
8,722,680Method of treating neurodegenerative diseases► Subscribe
8,680,105Method of treating down's syndrome► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Julphar
Boehringer Ingelheim
Moodys
McKinsey
Healthtrust
Deloitte
Chubb
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot